title: Factor XIa and tissue factor activity in patients with coronary artery disease.
abstract: It has been established that inflammation and enhanced pro-coagulant activity are associated with the pathogenesis of atherosclerotic vascular disease. We evaluated and compared the contributions of the factor (F)XIa and tissue factor (TF) activity in plasma of patients with coronary artery disease (CAD). Citrate plasma was obtained prior to therapy from 53 patients with stable angina (29 with a history of previous myocardial infarction; CAD-MI) and 30 with acute coronary syndrome (ACS) within 12 hours from pain onset. Four ACS patients treated with heparin were excluded. FXIa and TF activity were determined in clotting assays based upon the prolongation of clotting time by inhibitory monoclonal antibodies. Twenty-five of 26ACS patients (96%) and 22 of 29 CAD-MI patients (76%) had quantifiable FXIa (50 +/- 33 and 42 +/- 45pM, respectively). Ten of 26 (38%) ACS patients and only three of 53 (6%) stable CAD patients showed TF activity (<0.4pM). No FXIa or TF activity was observed in age-matched healthy controls (n = 12). For both CAD-MI and ACS patients, there were correlations (p < 0.05) between FXIa and interleukin-6 (R(2) = 0.59 and 0.39, respectively) and between FXIa and TAT (R(2) = 0.64 and 0.63, respectively). In conclusion, the majority of ACS and CAD-MI patients have circulating FXIa that correlates with markers of coagulation and inflammation.
authors.affiliation: University of Vermont, Department of Biochemistry, Burlington, Vermont, USA.
authors.forename: Saulius
authors.initials: S
authors.lastname: Butenas
authors.forename: Anetta
authors.initials: A
authors.lastname: Undas
authors.forename: Matthew T
authors.initials: MT
authors.lastname: Gissel
authors.forename: Konstanty
authors.initials: K
authors.lastname: Szuldrzynski
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Zmudka
authors.forename: Kenneth G
authors.initials: KG
authors.lastname: Mann
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood* / Q000209:etiology; D000368:Aged; D000787:Angina Pectoris / Q000097:blood* / Q000209:etiology; D000990:Antithrombin III; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation; D001780:Blood Coagulation Tests; D016022:Case-Control Studies; D003324:Coronary Artery Disease / Q000097:blood / Q000150:complications*; D015951:Factor Xa / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000209:etiology; D010447:Peptide Hydrolases / Q000097:blood; D013925:Thromboplastin / Q000378:metabolism*
chemical_list: D015415:Biomarkers; C508600:IL6 protein, human; D015850:Interleukin-6; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D013925:Thromboplastin; D010447:Peptide Hydrolases; D015951:Factor Xa